+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening



Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening



Plos one 12(3): E0172864



The ColonCancerCheck screening program for colorectal cancer (CRC) in Ontario, Canada, is considering switching from biennial guaiac fecal occult blood test (gFOBT) screening between age 50-74 years to the more sensitive, but also less specific fecal immunochemical test (FIT). The aim of this study is to estimate whether the additional benefits of FIT screening compared to gFOBT outweigh the additional costs and harms. We used microsimulation modeling to estimate quality adjusted life years (QALYs) gained and costs of gFOBT and FIT, compared to no screening, in a cohort of screening participants. We compared strategies with various age ranges, screening intervals, and cut-off levels for FIT. Cost-efficient strategies were determined for various levels of available colonoscopy capacity. Compared to no screening, biennial gFOBT screening between age 50-74 years provided 20 QALYs at a cost of CAN$200,900 per 1,000 participants, and required 17 colonoscopies per 1,000 participants per year. FIT screening was more effective and less costly. For the same level of colonoscopy requirement, biennial FIT (with a high cut-off level of 200 ng Hb/ml) between age 50-74 years provided 11 extra QALYs gained while saving CAN$333,300 per 1000 participants, compared to gFOBT. Without restrictions in colonoscopy capacity, FIT (with a low cut-off level of 50 ng Hb/ml) every year between age 45-80 years was the most cost-effective strategy providing 27 extra QALYs gained per 1000 participants, while saving CAN$448,300. Compared to gFOBT screening, switching to FIT at a high cut-off level could increase the health benefits of a CRC screening program without considerably increasing colonoscopy demand.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 059785832

Download citation: RISBibTeXText

PMID: 28296927


Related references

Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program. Cancer Prevention Research 12(5): 327-334, 2019

Cost-effectiveness of colorectal cancer screening with an immunochemical fecal occult blood test versus guaiac FOBT. American Journal of Gastroenterology 98(9 Suppl.): S221-S222, 2003

Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Canadian Journal of Gastroenterology 26(3): 131-147, 2012

Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Preventive Medicine 50(5-6): 297-299, 2010

Screening for colorectal cancer by immunochemical fecal occult blood testing. Japanese Journal of Cancer Research 87(10): 1011-1024, 1996

A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. International Journal of Cancer 128(10): 2415-2424, 2011

Cost-effectiveness of colorectal cancer screening with an immunochemical fecal occult blood test (FOBT) versus guaiac FOBT. American Journal of Gastroenterology 98: S221-S222, 2003

Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135(1): 82-90, 2008

Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. International Journal of Cancer 128(8): 1908-1917, 2011

Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing. Bmc Cancer 15: 705, 2015

ACP Journal Club. Colorectal cancer screening with fecal immunochemical testing had higher adherence than screening with guaiac-based FOBT. Annals of Internal Medicine 153(8): Jc4-Jc5, 2010

Mo1175 Increment With Age of Proximal Advanced Neoplasia in Three Rounds of a Colorectal Cancer Screening by Immunochemical Fecal Occult Blood Testing. Gastroenterology 144(5): S-598, 2013

T1109 Colorectal Cancer Screening with the Addition of Flexible Sigmoidoscopy to Guaiac-Based Fecal Occult Blood Testing: A Population-Based Controlled Trial. Gastroenterology 134(4): A-485, 2008

Su1215 Systematic Review and Bivariate/Hsroc Meta-Analysis of Immunochemical and Guaiac Fecal Occult Blood Tests for Colorectal Cancer Screening. Gastroenterology 146(5): S-404, 2014

Mass screening for colorectal cancer with the guaiac fecal occult blood test: possible population benefits, proven individual risks. Presse Medicale 37(2 Pt 2): 363-366, 2008